Company Overview

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies.

Read More Corporate Presentation Corporate Fact Sheet

Latest News

IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine

February 22, 2024

IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

December 11, 2023

IMUNON’s VP of R&D to Present at the Vaccines Summit-2023

November 14, 2023

Financial Events

Imunon’s Third Quarter 2023 Financial Results

November 14, 2023 at 10:00 AM EST

H.C. Wainwright 25th Annual Global Investment Conference

September 11, 2023